ETFIQData as of Nov 18, 2026. · etfiq.com/funds/hrts

HRTS Fact Sheet: Tema Heart & Health ETF

Share
$37.75
close, Nov 18, 2026

Over the year to Nov 18, 2026, HRTS returned +10.3% in total and charged 0.75% a year.

1-year total return
+10.3%
to Nov 18, 2026
Expense ratio
0.75%
a year
Net assets
$57m
on Nov 17, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

HRTS $11,025 +10.3% · VOO $11,188 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+2.3%
3 months−2.9%
Year to date+7.0%
1 year+10.3%
Since launch+45.8%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
ELI LILLY & CO12.63%
THERMO FISHER SCIENTIFIC INC5.43%
ROCHE HOLDING AG4.39%
MERCK & CO INC4.06%
BRIDGEBIO PHARMA INC3.80%
KODIAK SCIENCES INC3.78%
GILEAD SCIENCES INC3.52%
DANAHER CORP3.15%
REVOLUTION MEDICINES INC3.05%
NOVO NORDISK A/S2.99%

HRTS top ten by weight, 46.8% of the fund, of its 45 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Actively managed · First traded Nov 21, 2023 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, HRTS Fact Sheet: Tema Heart & Health ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/hrts/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/hrts.